Retraction to: Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells (J Cell Biochem, 2011, 112, (78-88), 10.1002/jcb.22770);Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 112, Issue 1, 2011, Pages 78-88

  Wang, Zhiwei ^a   Li, Yiwei ^a   Ahmad, Aamir ^a   Banerjee, Sanjeev ^a   Azmi, Asfar S ^a   Kong, Dejuan ^a   Wojewoda, Christine ^a   Miele, Lucio ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Akt; Apoptosis; Cell growth; FoxM1; NOTCH 1; Prostate cancer

Indexed keywords

DOCETAXEL; GENISTEIN; MEMBRANE PROTEIN; NOTCH1 RECEPTOR; PROTEIN FOXM1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SHORT TANDEM REPEAT; SIGNAL TRANSDUCTION; SOYBEAN; TUMOR XENOGRAFT;

GLYCINE MAX;

EID: 78651333282     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25587     Document Type: Erratum

References (41)

1. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH. 2005. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65:9064-9072.
2. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH. 2007a. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 67:3818-3826.
3. Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH. 2007b. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 120:906-917. (Pubitemid 46175414)
4. Banerjee S, Li Y, Wang Z, Sarkar FH. 2008. Multi-targeted therapy of cancer by genistein. Cancer Lett 269:226-242.
5. Bektas N, Haaf A, Veeck J, Wild PJ, Luscher-Firzlaff J, Hartmann A, Knuchel R, Dahl E. 2008. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 8:1-9.
6. Bin HB, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, Mukhtar H. 2009. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 15:452-459.
7. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. 2007. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7:1-21.
8. Chiuri VE, Silvestris N, Lorusso V, Tinelli A. 2009. Efficacy and safety of the combination of docetaxel (taxotere) with targeted therapies in the treatment of solid malignancies. Curr Drug Targets 10:982-1000.
9. Falci C, Morello E, Droz JP. 2009. Treatment of prostate cancer in unfit senior adult patients. Cancer Treat Rev 35:522-527.
10. Gartel AL. 2008. FoxM1 inhibitors as potential anticancer drugs. Expert Opin Ther Targets 12:663-665.
11. Gartel AL. 2010. A new target for proteasome inhibitors: FoxM1. Expert Opin Invest Drugs 19:235-242.
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
13. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Lyubimov A, Costa RH. 2006. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 66:1712-1720.
14. Kopan R, Ilagan MX. 2009. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 137:216-233.
15. Leong KG, Gao WQ. 2008. The Notch pathway in prostate development and cancer. Differentiation 76:699-716.
16. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. 2005a. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65:6934-6942.
17. Li Y, Hong X, Hussain M, Sarkar SH, Li R, Sarkar FH. 2005b. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 4:389-398. (Pubitemid 40443924)
18. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH. 2005c. Gene expression profiling revealed novel mechanism of action of taxotere and furtulon in prostate cancer cells. BMC Cancer 5:1-13.
19. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH. 2006. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 66:4816-4825.
20. Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, Huang S, Tan D, Xie K. 2009. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res 69:3501-3509.
21. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, Qiu R, Pinnix CC, Li X, Herlyn M. 2006. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66:4182-4190.
22. Major ML, Lepe R, Costa RH. 2004. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylationdependent recruitment of p300/CBP coactivators. Mol Cell Biol 24:2649-2661.
23. Miele L. 2006. Notch signaling. Clin Cancer Res 12:1074-1079.
24. Miele L, Miao H, Nickoloff BJ. 2006. Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6:313-323.
25. Osipo C, Golde TE, Osborne BA, Miele LA. 2008. Off the beaten pathway: The complex cross talk between Notch and NF-kappaB. Lab Invest 88:11-17.
26. Palomero T, Dominguez M, Ferrando AA. 2008. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 7:965-970.
27. Pandit B, Gartel AL. 2010. New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate 70:825-833.
28. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, Lau LF, Costa RH, Raychaudhuri P. 2009. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 28:2908-2918.
29. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL. 2006. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box m1. Cancer Res 66:9731-9735.
30. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. 2008. Rational targeting of Notch signaling in cancer. Oncogene 27:5124-5131.
31. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. 2001. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 61:7291-7297.
32. Villaronga MA, Bevan CL, Belandia B. 2008. Notch signaling: A potential therapeutic target in prostate cancer. Curr Cancer Drug Targets 8:566-580.
33. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. 2006a. Downregulation of Notch-1 inhibits invasion by inactivation of nuclear factor- {kappa}B, vascular endothelial growth factor, and matrix metalloproteinase- 9 in pancreatic cancer cells. Cancer Res 66:2778-2784.
34. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. 2006b. Downregulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5:483-493.
35. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. 2007. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300.
36. Wang Z, Li Y, Banerjee S, Sarkar FH. 2008. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res 28:3621-3630.
37. Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, Mohammad RM. 2009. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: Involvement of Notch-1 signaling pathway. Cancer Res 69:2757-2765.
38. Wang Z, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. 2010a. Forkhead box M1 transcription factor: A novel target for cancer therapy. Cancer Treat Rev 36:151-156.
39. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH. 2010b. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 109:726-736.
40. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L. 2002. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8:979-986.
41. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH. 2006. Downregulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 119:2071-2077.